Technical bulletin provides details on updated CDC guidance for general public Note: Health care professionals working in licensed health care facilities should continue to use Ending Isolation and Precautions for People with COVID-19. Also, CDC’s COVID-19 Community Levels recommendations do not apply in health care settings, such as hospitals and nursing homes. Instead, health care settings should continue to use community transmission rates and continue to follow CDC’s Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.
On August 11, 2022, the Centers for Disease Control and Prevention (CDC) updated their isolation guidance for members of the general public with COVID-19. Individuals with COVID-19 can spread the virus to others but there are precautions that COVID-positive individuals can take to prevent spreading it to others: isolation, masking and avoiding contact with people who are at high risk of getting very sick. Isolation is used to separate people with confirmed or suspected COVID-19 from those without COVID-19. These recommendations do not change based on COVID-19 Community Levels. See the additional information linked here about treatments that may be available to COVID-positive individuals. The Nevada Department of Health and Human Services has drafted a technical bulletin, titled “Updated Guidance: Isolation and Precautions for People with COVID-19,” with more details, including details on isolation duration for individuals with and without symptoms, masking and reporting to local health authorities. Visit the technical bulletins web page and see the “COVID-19” section. For more information, guidance and resources about the COVID-19 response in Nevada, visit https://nvhealthresponse.nv.gov/.
2 Comments
Technical bulletin outlines required reporting to state or local health authorities Since May 2022, the Centers for Disease Control and Prevention (CDC) has been urging health care providers in the United States to be on alert for patients who present with rash illnesses consistent with monkeypox. Distinguishing features of the rash include papules, vesicles, pustules or scabs that are deep-seated, firm or rubbery, and have well-defined round borders. Vesicular or pustular stages of the lesions are often umbilicated (i.e., have a dent in the middle of them). They may be painful, painless or itchy. People with monkeypox may develop symptoms including fever, headache, muscle aches, exhaustion or swollen lymph nodes during the prodromal period preceding the rash or with the rash. (CDC – Update for Clinicians on Testing and Treatment for Monkeypox)
Effective immediately, all suspect and confirmed cases (positive, negative, equivocal) of monkeypox are reportable to the Division of Public and Behavioral Health (DPBH) or local health authority (Southern Nevada Health District, Washoe County Health District, or Carson City Health and Human Services) using Nevada’s Confidential Morbidity Report Form, located online or through existing electronic laboratory reporting mechanisms. The results should be reported within 24 hours of testing. These data will inform prevention measures, contribute to the understanding of this outbreak and can assist in predicting increases in testing demand and planning for potential supply chain issues. For full details, read the technical bulletin linked here. Technical bulletin provides details on both pre- and post-exposure prophylaxis Currently, two vaccines licensed by the U.S. Food and Drug Administration (FDA) are available for preventing monkeypox infection: JYNNEOS and ACAM2000. Both can be used before and after exposure to monkeypox, however ACAM2000 carries a higher potential for more serious side effects and adverse events than JYNNEOS and may not be an appropriate option for most patients. Because of the risks associated with ACAM2000, the Nevada Department of Health and Human Services (DHHS) has opted to order supplies of JYNNEOS through the Strategic National Stockpile (SNS). However, supplies of JYNNEOS are extremely limited. If ACAM2000 is clinically necessary for a specific person after consultation with CDC, the doses can be ordered at that time.
For details on both vaccines, including pre- and post-exposure prophylaxis guidance and reporting information, read the technical bulletin, Monkeypox Virus Vaccine Guidance and Recommendations. Technical bulletin provides guidance for clinicians working with patient affected by outbreak As of August 2, 2022, there have been 5,811 confirmed monkeypox/Orthopoxvirus cases reported in 47 U.S. states, the District of Columbia and Puerto Rico. The state of Nevada has a total of 25 monkeypox cases, with 24 in Clark County and 1 in Washoe County. The Nevada Department of Health and Human Services has published a technical bulletin with information for health care providers, hospitals, laboratories and local health authorities with details about transmission, symptoms, clinical recognition, testing and reporting to help in treating patients affected by this outbreak.
Full details are available in the technical bulletin linked here. |
AuthorThe Bureau of Health Care Quality and Compliance (HCQC) licenses medical and other health facilities, child care facilities and personnel, and medical laboratories and personnel in Nevada. HCQC also conducts compliance surveys and takes complaints. Archives
October 2023
Categories
All
|